Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

New use of mangiferin compounds

A technology of mangiferin and compounds, applied in the field of medicine, can solve problems such as gout and hyperuricemia that have not been seen before

Active Publication Date: 2008-07-09
KPC PHARM INC
View PDF0 Cites 20 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, none of the above compounds have been reported for the treatment of gout and hyperuricemia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New use of mangiferin compounds
  • New use of mangiferin compounds

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0012] Effects of mangiferin, isomangiferin and norathyriol on hyperuricemia mice

[0013] Healthy male Kunming mice, weighing 18-22 g, were provided by the Experimental Animal Center of Kunming Medical College [Experimental Animal Production License Number: SCXK (Dian) 2005-2008]. Breeding conditions: room temperature is 22±2°C, relative humidity is 60-70%.

[0014] Fifty Kunming mice were randomly divided into normal control group, hyperuricemia model group, mangiferin, isomangiferin and norathyriol groups. The test compound was prepared into a suspension with 0.5% sodium carboxymethylcellulose (0.5% CMC-Na), and administered by intragastric administration at 3.13 mg / kg, twice a day, 5 doses in total.

[0015] The uricase inhibitor oxonic acid is selected as a chemical inducer to inhibit the activity of uricase and cause hyperuricemia. Animals were intraperitoneally injected mice with oxonic acid potassium salt (product of Sigma Company) at a dose of 400 mg / kg 2 h before b...

Embodiment 2

[0021] Study on the dose-effect relationship of mangiferin in reducing hyperuricemia

[0022] Seventy healthy male Kunming mice, weighing 18-22 g, were provided by the Experimental Animal Center of Kunming Medical College [Experimental Animal Production License Number: SCXK (Dian) 2005-2008]. Animals were randomly divided into normal control group, hyperuricemia model group, mangiferin 0.88, 1.56, 3.13 and 6.25 mg / kg dose groups and allopurinol (3.13 mg / kg) positive control group. The test compound was prepared into a suspension with 0.5% sodium carboxymethylcellulose (0.5% CMC-Na), administered orally, twice a day, 5 doses in total.

[0023] The hyperuricemia modeling method is the same as before, that is, the mice are intraperitoneally injected with 400 mg / kg oxonic acid potassium salt 2 hours before blood sampling to cause hyperuricemia, and the normal control group is injected with an equal volume of 0.5% CMC-Na solution, and irrigated after 1 hour. The last dose of the t...

Embodiment 3

[0028] The influence of embodiment 3 mangiferin on xanthine oxidase

[0029] Xanthine oxidase (EC 1.1.3.22) is a product of Sigma Company, prepared with PBS to an appropriate concentration for use. Mangiferin was prepared into a series of concentrations with PBS for use, and DMSO was used to aid in dissolution. Xanthine oxidase assay kit is a product of Nanjing Jiancheng Bioengineering Institute.

[0030] After incubating the mangiferin solution with serial concentrations and xanthine oxidase at 37°C for 30 minutes, the activity of xanthine oxidase was measured with a xanthine oxidase assay kit. The results showed that mangiferin had a certain inhibitory effect on the activity of xanthine oxidase ( table 3).

[0031] Table 3: Effect of mangiferin on xanthine oxidase (x±s, n=4)

[0032] group

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a novel purpose of mangiferin compound for preventing and remedying hyperuricemia and gout. A study shows that the mangiferin compound has very strong anti-gout effect; 0.002mmol / kg (0.78mg / kg) of the dosage can reduce the serum uric acid level of a mouse with the hyperuricemia obviously; the mangiferin compound has higher activity than allopurinol and has little toxic and side effect; the maximum gastric infusion tolerance dose of the mouse is 47.4mmol / kg (20g / kg), which is lower than that of current clinical applied anti-gout medicines, such as colchicines, the allopurinol, sulphinpyrazone, etc.; the present invention can be applied to prepare for oral anti-gout medicines and health care products.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the new application of the compound in the prevention and treatment of gout. Background technique [0002] Gout is a group of metabolic diseases caused by excessive production of uric acid and / or decreased excretion of uric acid due to purine metabolic disorders, and accumulation of uric acid in the body. Uric acid is the product of human purine metabolism, and hyperuricemia is the main biochemical basis of gout (Hyon K.Choi, David B.Mount, and Anthony M.Reginato.Pathogenesis of Gout.Annals of Internal Medicine.2005, 143(7): 499-516). At present, there are very limited drugs for the treatment of gout and hyperuricemia, mainly allopurinol, benzbromarone and colchicine, etc. These drugs have large side effects and are often not tolerated by patients, which limits their use to a certain extent. Therefore, finding new anti-gout and hyperuricemia drugs with high efficiency and low ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61P19/06
Inventor 李玲陈植和
Owner KPC PHARM INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com